welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update
Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
“We have continued to advance our programs for Duchenne muscular dystrophy over the last few months, particularly our lead microdystrophin gene therapy candidate, SGT-001. Building on our findings from the preliminary Phase I/II clinical data that we announced in February, we initiated dosing at 2E14 vg/kg in the second cohort of patients,” said Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid Biosciences. “Now, we are working to progress as quickly as possible, and we look forward to providing additional data later this year.”
rareRelated
-
Statement from FDA Commissioner Scott Gottlieb, M.D. on agency’s efforts to advance development of gene therapiesOnce just a theory, gene therapies are n...
-
Personalized gene and cell therapy for Duchenne Muscular DystrophyDystrophinopathies are diseases caused b...
-
Update in Duchenne and Becker Muscular DystrophyPurpose of Review: The purpose of this ...
-
Duchenne Muscular Dystrophy Awaits Gene TherapySolid’s gene therapy disappoints in th...
-
Microdystrophin Gene Transfer Study in Adolescents and Children With DMDThis is a randomized, controlled, open-l...
-
Emerging Therapies for Duchenne Muscular Dystrophyhttps://www.youtube.com/watch?v=4qtcyz4U...
-
Gene Therapy as a Potential Therapeutic Option for Duchenne Muscular Dystrophy: A Qualitative Preference Study of Pa...Objectives: Duchenne muscular dystrophy...
